📉 The Financial Deep Dive
Metropolis Healthcare Limited has announced robust financial results for the third quarter and nine months ended December 31, 2025, marked by significant revenue acceleration, although profitability shows mixed trends. The company also revealed a substantial 3:1 bonus equity share issue.
The Numbers:
- Standalone Performance (Q3 FY2026): Revenue from operations surged by 60.25% year-on-year to ₹33,478.10 Lakhs. Profit After Tax (PAT) grew 16.89% to ₹3,203.27 Lakhs. Earnings Per Share (EPS) (Basic) rose to ₹6.18 from ₹5.35 in the prior year.
- Consolidated Performance (Q3 FY2026): Revenue increased by 25.76% to ₹40,590.97 Lakhs. PAT saw a stronger growth of 33.72%, reaching ₹4,208.71 Lakhs. Basic EPS improved to ₹7.99 from ₹6.12.
- Standalone Performance (Nine Months FY2026): Revenue grew 12.11% to ₹1,01,412.66 Lakhs. PAT increased by 13.18% to ₹11,424.73 Lakhs. Basic EPS stood at ₹20.50.
- Consolidated Performance (Nine Months FY2026): Revenue jumped 23.86% to ₹1,22,116.43 Lakhs. PAT growth was minimal at 0.67%, amounting to ₹11,628.26 Lakhs. Basic EPS was ₹28.50.
While revenue growth is commendable across both standalone and consolidated books, the profit quality shows divergence. Standalone Q3 PAT margin compressed by approximately 367 basis points to 9.57% from 13.24% in Q3 FY2025, indicating cost pressures or pricing challenges on a standalone basis. Conversely, consolidated Q3 PAT margin expanded by 62 bps to 10.37%. However, the consolidated nine-month PAT margin saw a significant compression of 220 bps to 9.52% from 11.72%, despite robust revenue growth, highlighting operational inefficiencies or higher costs at the group level over the longer period. Exceptional items, primarily due to the incremental impact of newly notified Labour Codes, amounted to ₹795.67 Lakhs (standalone) and ₹909.65 Lakhs (consolidated), further impacting reported profits.
The Grill:
No management call transcript was provided, hence no specific analyst grilling details are available.
Risks & Outlook:
A significant risk remains the pending appeals before the Income Tax Appellate Tribunal (ITAT). An initial demand of ₹7,306.46 Lakhs was reduced to ₹3,880 Lakhs, against which the company has made a provision of ₹1,964.04 Lakhs. This represents a material contingent liability. The sale of the EQAS Division to a wholly-owned subsidiary for up to ₹1.25 crore is a minor divestment, as it contributed only ₹84.4 Lakhs to FY2025 revenue. The company's ability to translate strong revenue into consistent profit growth, especially at the consolidated level, and manage operational costs will be key. The 3:1 bonus issue, while a positive for shareholders, does not impact the company's fundamentals but can boost liquidity and potentially shareholder confidence.